Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arrowhead Pharmaceuticals

11.24
-0.1100-0.97%
Post-market: 11.240.00000.00%19:11 EDT
Volume:2.38M
Turnover:26.62M
Market Cap:1.54B
PE:-2.18
High:11.51
Open:11.27
Low:10.92
Close:11.35
Loading ...

Arrowhead Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
27 Nov 2024

Arrowhead Pharmaceuticals Fiscal Q4 Loss Widens, Revenue Declines

MT Newswires Live
·
27 Nov 2024

Arrowhead reports FY24 EPS ($5.00), consensus ($4.53)

TIPRANKS
·
27 Nov 2024

Arrowhead Pharma FY 2024 GAAP EPS $(5.00) Misses $(4.45) Estimate, Sales $3.551M Miss $74.932M Estimate

Benzinga
·
27 Nov 2024

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

THOMSON REUTERS
·
27 Nov 2024

Sector Update: Health Care Stocks Higher Late Afternoon

MT Newswires Live
·
27 Nov 2024

Sarepta Therapeutics’ Strategic Alliance with Arrowhead Pharmaceuticals Secures Future Growth

TIPRANKS
·
27 Nov 2024

Sector Update: Health Care Stocks Advance Tuesday Afternoon

MT Newswires Live
·
27 Nov 2024

Sarepta deal with Arrowhead a ‘prudent move,’ says Leerink

TIPRANKS
·
27 Nov 2024

Sarepta deal with Arrowhead creates major catalysts, says BMO Capital

TIPRANKS
·
27 Nov 2024

Arrowhead Pharmaceuticals Shares Jump 25.1% After Co Announces Global License With Sarepta Therapeutics for Multiple Clinical & Preclinical Programs

THOMSON REUTERS
·
26 Nov 2024

Morning Movers: Dick’s Sporting jumps and Kohl’s sinks following earnings

TIPRANKS
·
26 Nov 2024

Arrowhead Pharmaceuticals Shares Jump 28% Premarket After Co Announces Global License With Sarepta Therapeutics for Multiple Clinical & Preclinical Programs

THOMSON REUTERS
·
26 Nov 2024

Arrowhead Pharma, Sarepta Therapeutics Sign Licensing, Partnership Deal for Clinical, Preclinical Programs

MT Newswires Live
·
26 Nov 2024

Arrowhead climbs after licensing deal with Sarepta

seekingalpha
·
26 Nov 2024

Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal

Dow Jones
·
26 Nov 2024

Sarepta: Co Will Nominate & Arrowhead Will Deliver Ind-Ready Constructs for 6 Targets Across Skeletal Muscle, Cardiac, CNS

THOMSON REUTERS
·
26 Nov 2024

Sarepta Therapeutics Inc - CEO Doug Ingram to Join Arrowhead Board

THOMSON REUTERS
·
26 Nov 2024

Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement With Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

THOMSON REUTERS
·
26 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
25 Nov 2024